Anti-Coagulants - Indonesia

Indonesia

Highlights

In Indonesia, the Anti-Coagulants market is expected to witness a significant growth in revenue.
By 2024, the projected revenue is estimated to reach US$95.27m.
This positive trend is expected to continue with an annual growth rate of 8.05% during the period of 2024-2029.
Consequently, the market volume is projected to reach US$140.30m by 2029.
When comparing the global market, United States is anticipated to generate the highest revenue.
In 2024, the projected revenue United States is estimated to be US$16.74bn.
Indonesia's growing demand for anti-coagulants is driven by an aging population and increasing prevalence of cardiovascular diseases.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

The demand for Anti-Coagulants in Indonesia has been on the rise in recent years.

Customer preferences: Indonesia's aging population is one of the primary drivers of the increasing demand for Anti-Coagulants. The country's elderly population is growing at a faster rate than the rest of the population, leading to more cases of cardiovascular diseases. Besides, the rise in the number of cases of obesity and diabetes is also contributing to the growth of the Anti-Coagulants market in Indonesia.

Trends in the market: One of the notable trends in the Anti-Coagulants market in Indonesia is the shift towards direct oral anticoagulants (DOACs) from traditional Vitamin K antagonists (VKAs). DOACs are more convenient for patients as they require less monitoring, have a lower risk of bleeding, and have a shorter half-life. The increasing availability of DOACs in Indonesia is driving the shift in preference. Additionally, there is an increasing trend towards the use of combination therapies, such as antiplatelets and anticoagulants, to reduce the risk of thrombosis.

Local special circumstances: Indonesia's healthcare system is still developing, and access to healthcare is limited in some regions. This situation has led to a high prevalence of self-medication, with many patients buying drugs over the counter. The lack of regulation in the sale of drugs has led to the availability of counterfeit drugs, which are often cheaper and more accessible to patients. The presence of counterfeit drugs in the market is a significant challenge for the Anti-Coagulants market in Indonesia.

Underlying macroeconomic factors: Indonesia's economy has been growing steadily in recent years, and this has led to an increase in the middle-class population. The rise in the middle class has led to an increase in demand for better healthcare services, including access to better drugs. Additionally, the government's efforts to improve the healthcare system, such as the introduction of the National Health Insurance (JKN), have led to an increase in the number of people seeking medical attention. This situation has contributed to the growth of the Anti-Coagulants market in Indonesia.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.